Journal of Clinical Endocrinology & Metabolism, Vol 78, 826-829, Copyright © 1994 by Endocrine Society

ARTICLES

Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma

F Pacini, M Fontanelli, L Fugazzola, R Elisei, C Romei, G Di Coscio, P Miccoli and A Pinchera
Istituto di Endocrinologia, University of Pisa, Italy.

To assess whether routine measurement of serum calcitonin (CT) could improve the preoperative diagnosis of sporadic medullary thyroid carcinoma (MTC), 1385 consecutive patients presenting for nodular thyroid disease during the year 1991 were submitted to serum CT determination and fine needle aspiration cytology (FNAC). The clinical diagnosis was nontoxic nodular goiter in 1197 (86.4%) patients, toxic multinodular goiter in 65 (4.7%), autonomously functioning thyroid nodule (AFTN) in 64 (4.6%), and autoimmune thyroid disease (Graves' disease or Hashimoto's thyroiditis) with nodule(s) in 59 (4.3%). As controls, 177 patients with nonnodular thyroid disease and 32 normal subjects were also studied. Patients with FNAC suspicious of any kind of thyroid carcinoma and patients with elevated basal and pentagastrin- stimulated serum CT, regardless of the results of FNAC, were submitted to surgery. Eight (0.57%) patients (7 with nontoxic nodular goiter and 1 with AFTN) had elevated basal serum CT levels, ranging between 55- 10,000 pg/mL. The pentagastrin test was abnormal in all of them. FNAC was suggestive of MTC in 2, thyroid carcinoma in 1, benign nodule in 3, and inadequate in 2. By histology, immunohistochemistry, and Northern blot analysis of total tumor RNAs, MTC was confirmed in all patients, including the 1 with AFTN, who had the association of microfollicular adenoma and a small MTC in the same lobe. After surgery, serum CT decreased to undetectable levels in 7 patients and remained undetectable in 6 of them during a mean follow-up of 22 months, although 1 of them had a positive response to pentagastrin. Forty-four patients in the group with normal serum CT levels had FNAC suspicious for differentiated thyroid carcinoma and were treated by surgery. Differentiated thyroid carcinoma, mostly papillary, was confirmed at histology in 43 subjects (3.1% of all thyroid nodules). In conclusion, the results of our study indicate that serum CT measurement is useful for the screening of sporadic MTC in patients with thyroid nodule(s). The prevalence of MTC, diagnosed by serum CT measurement in a 12-month period, among an unselected series of 1385 patients with nodular thyroid disease was surprisingly high: 0.57% of all thyroid nodules and 15.7% of all thyroid carcinomas. Serum CT measurement was superior to FNAC in suggesting the diagnosis of MTC and was devoid of falsely positive results. Increasing the diagnostic accuracy helped the surgeon to perform more radical treatment of MTC, thus achieving frequent normalization of postoperative serum CT levels. Whether this result indicates definitive cure remains to be established on the basis of longer follow-up.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				K. Cheung, S. A. Roman, T. S. Wang, H. D. Walker, and J. A. Sosa Calcitonin Measurement in the Evaluation of Thyroid Nodules in the United States: A Cost-Effectiveness and Decision Analysis J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2173 - 2180. [Abstract] [Full Text] [PDF]

				M. d'Herbomez, P. Caron, C. Bauters, C. Do Cao, J.-L. Schlienger, R. Sapin, L. Baldet, B. Carnaille, J.-L. Wemeau, and the French Group GTE (Groupe des Tumeurs Endocrine Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking Eur. J. Endocrinol., December 1, 2007; 157(6): 749 - 755. [Abstract] [Full Text] [PDF]

				P. Miccoli, M. N Minuto, C. Ugolini, E. Molinaro, F. Basolo, P. Berti, A. Pinchera, and R. Elisei Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer Endocr. Relat. Cancer, December 1, 2007; 14(4): 1099 - 1105. [Abstract] [Full Text] [PDF]

				I. Borget, G. De Pouvourville, and M. Schlumberger Calcitonin Determination in Patients with Nodular Thyroid Disease J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 425 - 427. [Full Text] [PDF]

				G. Costante, D. Meringolo, C. Durante, D. Bianchi, M. Nocera, S. Tumino, U. Crocetti, M. Attard, M. Maranghi, M. Torlontano, et al. Predictive Value of Serum Calcitonin Levels for Preoperative Diagnosis of Medullary Thyroid Carcinoma in a Cohort of 5817 Consecutive Patients with Thyroid Nodules J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 450 - 455. [Abstract] [Full Text] [PDF]

				S. M. Baumgartner-Parzer, R. Lang, L. Wagner, G. Heinze, B. Niederle, K. Kaserer, W. Waldhausl, and H. Vierhapper Polymorphisms in Exon 13 and Intron 14 of the RET Protooncogene: Genetic Modifiers of Medullary Thyroid Carcinoma? J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6232 - 6236. [Abstract] [Full Text] [PDF]

				M. R. Castro and H. Gharib Continuing Controversies in the Management of Thyroid Nodules Ann Intern Med, June 7, 2005; 142(11): 926 - 931. [Abstract] [Full Text] [PDF]

				L. A. Diehl, V. Garcia, S. J. Bonnema, L. Hegedus, C. C. Albino, H. Graf, and for the Latin American Thyroid Society Management of the Nontoxic Multinodular Goiter in Latin America: Comparison with North America and Europe, an Electronic Survey J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 117 - 123. [Abstract] [Full Text] [PDF]

				S. P. Hodak and K. D. Burman The Calcitonin Conundrum--Is It Time for Routine Measurement of Serum Calcitonin in Patients with Thyroid Nodules? J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 511 - 514. [Full Text] [PDF]

				G. Karanikas, A. Moameni, C. Poetzi, G. Zettinig, K. Kaserer, C. Bieglmayer, B. Niederle, R. Dudczak, and C. Pirich Frequency and Relevance of Elevated Calcitonin Levels in Patients with Neoplastic and Nonneoplastic Thyroid Disease and in Healthy Subjects J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 515 - 519. [Abstract] [Full Text] [PDF]

				R. Elisei, V. Bottici, F. Luchetti, G. Di Coscio, C. Romei, L. Grasso, P. Miccoli, P. Iacconi, F. Basolo, A. Pinchera, et al. Impact of Routine Measurement of Serum Calcitonin on the Diagnosis and Outcome of Medullary Thyroid Cancer: Experience in 10,864 Patients with Nodular Thyroid Disorders J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 163 - 168. [Abstract] [Full Text] [PDF]

				L. Hegedus, S. J. Bonnema, and F. N. Bennedbaek Management of Simple Nodular Goiter: Current Status and Future Perspectives Endocr. Rev., February 1, 2003; 24(1): 102 - 132. [Abstract] [Full Text] [PDF]

				G. Vitale, A. Ciccarelli, M. Caraglia, M. Galderisi, R. Rossi, S. Del Prete, A. Abbruzzese, and G. Lupoli Comparison of Two Provocative Tests for Calcitonin in Medullary Thyroid Carcinoma: Omeprazole vs Pentagastrin Clin. Chem., September 1, 2002; 48(9): 1505 - 1510. [Abstract] [Full Text] [PDF]

				S. J. Bonnema, F. N. Bennedbak, P. W. Ladenson, and L. Hegedus Management of the Nontoxic Multinodular Goiter: A North American Survey J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 112 - 117. [Abstract] [Full Text] [PDF]

				M. L. Brandi, R. F. Gagel, A. Angeli, J. P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R. G. Gheri, A. Libroia, et al. CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5658 - 5671. [Abstract] [Full Text] [PDF]

				E J Lamb, R M Heddle, and A Ellis Spuriously elevated plasma calcitonin in a patient with a thyroid nodule not associated with medullary thyroid carcinoma Postgrad. Med. J., May 1, 1999; 75(883): 289 - 291. [Abstract] [Full Text]

				H. Vierhapper, W. Raber, C. Bieglmayer, K. Kaserer, A. Weinhausl, and B. Niederle Routine Measurement of Plasma Calcitonin in Nodular Thyroid Diseases J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1589 - 1593. [Abstract] [Full Text] [PDF]

				P. K. Horvit and R. F. Gagel The Goitrous Patient with an Elevated Serum Calcitonin--What to Do? J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 335 - 337. [Full Text] [PDF]

				P. Niccoli, N. Wion-Barbot, P. Caron, J.-F. Henry, C. de Micco, J.-P. Saint Andre, J.-C. Bigorgne, E. Modigliani, and B. Conte-Devolx Interest of Routine Measurement of Serum Calcitonin: Study in a Large Series of Thyroidectomized Patients J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 338 - 341. [Abstract] [Full Text] [PDF]